The aim of this study was to detect the prevalence of the polymorphisms of growth arrest-
Introduction
Sticky platelet syndrome (SPS) was described by Holliday at the 9th Conference on Stroke and Cerebral Circulation in Arizona in 1983. The results of recent studies suggest SPS to be a common cause of arterial and venous thrombosis. According to Mammen and Bick, SPS is the second most common hereditary thrombophilia after resistance to activated protein C (APC-R) and the most common thrombophilia associated with arterial thrombosis with the incidence of 21% approximately. [1] [2] [3] Clinical signs of SPS usually include otherwise unexplained arterial and venous thrombotic events that occur especially in stressful situations, probably due to higher level of epinephrine (EPI), and they are frequently recurrent under oral anticoagulant therapy (warfarin). 1, 3, 4 It is interesting that patients with SPS sometimes have migraine headache, but their family members often complain of this symptom. [5] [6] [7] Sticky platelet syndrome was even identified as a cause of kidney graft dysfunction due to graft infarction or of thromboembolic complication in transplant recipients during immunosuppressive drug administration. 8 According to Bick, SPS is the second most common thrombophilia (after antiphospholipid syndrome) that causes recurrent spontaneous abortions or fetal loss syndrome. [9] [10] [11] Sticky platelet syndrome is diagnosed by aggregometry according to the method of Mammen with the use of 3 low concentrations of adenosine diphosphate (ADP) and EPI. 3, 12 Aggregation induced by collagen, ristocetin, arachidonic acid, and thrombin is normal, and plasma levels of b-thromboglobulin and platelet factor 4 (PF4) are not elevated in these patients. Sticky platelet syndrome is classified as type I (hyperaggregation after ADP and EPI), type II (hyperaggregation after EPI alone), and type III (hyperaggregation after ADP alone). Sticky platelet syndrome type II seems to be the most common. 1, 3 The etiology of SPS is still uncertain. It is supposed that glycoprotein receptors on the platelet surface membrane may be involved, and thus their abnormality leads to platelet hyperfunction in patients with SPS. Abnormalities of GPIIb/IIIa (CD41/61) and GPIa/IIa (CD29/49b) were studied, but the underlining cause of SPS has not been discovered. 2, 4 In recent years, some authors suggested that growth arrestspecific gene 6 (Gas6) protein may be engaged in the etiopathogenesis of SPS. Gas6 protein is a product of Gas6 that seems to be involved in the thrombus formation. [13] [14] [15] [16] It is present in a-granules and belongs to the vitamin K-dependent protein family. Gas6 has a high structural homology with natural anticoagulant protein S, having 40% sequence identity, and interacts with Axl/Sky/Mer tyrosine kinases. 13, 14, 17, 18 The mechanism of Gas6 protein has not been clear yet, but some authors suggest that it acts relatively late and enhances platelet action following their activation by primary inducers. Gas6 protein has been reported in mouse model to enhance platelet aggregation by affecting the function of both a-2-adrenergic and ADP receptors. Gas6-deficient mouse models have shown a decreased platelet aggregation and secretion, especially at low agonist concentrations. 13 Gas6-deficient mice were found to be resistant to thrombosis due to defective platelet function and protected against fatal thromboembolism induced by collagen or EPI. 15, 16 The loss of Gas6 protein receptors does not prevent initial platelet aggregation but impairs subsequent stabilization of platelet aggregates, at least in part by reducing signaling and platelet granule secretion. 19 On the other side, Gas6-defective mice did not have spontaneous bleeding. This may also open a new point of view on the antithrombotic therapy, and Gas6 inhibition may be both an efficacious and a safe means of anticoagulant therapy. 18, 20, 21 Muñoz and coworkers 22 investigated the prevalence of Gas6 polymorphism (Gas6 c.834 þ 7G > A) in patients with stroke. They found out that allele A was less associated with stroke because it was rare in patients with stroke. AA genotype was related to decreased risk of thrombosis. 22 These results were consistent with the findings of several studies in mouse models described above. Thus, it could be supposed that allele G might be ''prothrombotic.''
The aim of this study was to assess the prevalence of Gas6 genotypes (Gas6 c. 834 þ 7G > A), especially the prevalence of allele G in patients with SPS.
Study Population and Methods
A total of 128 patients with SPS (42 men with the mean age of 45.1 + 15.1 years and 86 women with the mean age of 41.1 + 13.9 years) who had arterial and venous thromboembolic episodes (stroke, transitory ischemic attacks, angina pectoris, myocardial infarction, recurrent venous thrombosis, and recurrent abortions) were included in the study. Sticky platelet syndrome was diagnosed by aggregometry (PACKS-4 aggregometer, Helena Laboratories, Beaumont, TX, USA) according to the method of Mammen. Three low concentrations of each inducer (ADP, EPI) were used. Sticky platelet syndrome was diagnosed according to the diagnostic criteria of Mammen and Bick. 1, 3, 12 The control group included 137 healthy individuals (67 men with the mean age of 43.31 + 8.47 years and 70 women with the mean age of 46.11 + 9.49 years), negative for SPS assessed by aggregometry, with no prior history of thrombosis.
After the approval of Ethical Board of Faculty and informed written consent, both patients with SPS and controls were examined for polymorphism Gas6 c. 834 þ 7G > A by polymerase chain reaction (PCR) method. Isolation of genomic DNA from the whole blood was performed by SiMaxTM Genomic DNA extraction kit made by SBS Genetech Co, Ltd., Beijing, China. Genotyping was realized by the length of restriction fragments polymorphism detection method. Primers for amplification reaction were designed as follows: Gas6_i8_F: 5 0 -CCCCGTTAGAATCTGCATGT-3 0 ; Gas6_i8_R: 5 0 -CCAGGTCTTCACGGAAGTGT-3 0 . Analyzed single nucleotide polymorphism (SNP) in Gas6 gene is characterized by position: c.834þ7G>A Gas6; refSNP: rs8191974, location: intron 8, restriction endonuclease: AlwN I (New England Biolabs, Ipswich, MA, USA).
The statistical comparison was performed with the use of standard methods for the analysis of binary data (as described in ''Statistics at Square One''). P values less than .05 were considered to be statistically significant. 23 
Results
Sticky platelet syndrome was classified as type I in 35 cases (27.3%), type II in 91 patients (71.1%), and type III in 2 patients (1.6%), respectively. Clinically, SPS was presented as an arterial thrombosis (myocardial infarction, stroke, transitory ischemic attack, peripheral artery thrombosis) in 70 (54.7%) patients, and venous thrombosis occurred (deep vein thrombosis and/or pulmonary embolism) in 45 (35.2%) patients. Fifteen (12.5%) women had recurrent spontaneous abortions and in 4 (3.1%) cases there were both arterial and venous thrombosis. These results are depicted in the Figure 1 .
In a group of 128 patients with SPS examined, there were 63 (49.2%) GG homozygotes, 53 (41.4%) GA heterozygotes, and 12 (9.4%) AA homozygotes. In a control group of 137 healthy individuals, there were 83 (60.6%) GG homozygotes, 42 (30.7%) GA heterozygotes, and 12 (8.7%) AA homozygotes. These results are shown in Table 1 and Figure 2 .
The significant differences (P value <.05) between the patients and the control groups were not detected. However, it is remarkable that allele G that might be associated with thrombosis (homozygous or heterozygous) is present in the majority of patients with SPS and controls. The prevalence of Gas6 genotypes in different types of SPS are depicted in the Table 2 .
Discussion
Gas6 protein is a platelet function amplifier that plays a significant role in thrombosis. This was confirmed by several studies in mouse models where Gas6 protein inhibition by antibodies or Gas6 protein receptors (Mer, Axl, Sky) blocking lead to the decreased risk of EPI-, collagen-, or stasis-induced thrombosis. Gas6-deficient animals were protected against fatal thrombosis, the development of thrombus was not so rapid, and the clot was significantly smaller than in Gas6-positive individuals. Thus, it was supposed that Gas6 protein works as an enhancer of platelet function after their initial activation after primary inducers (ADP, EPI, collagen, etc), and it promotes platelet aggregation and thrombus stabilization. 13, 18, 19 Muñoz has described the association of Gas6 polymorphisms (Gas6 c. 834 þ 7G > A) with stroke and has defined the allele A as less common in patients with stroke. 14, 22 This study was performed to assess the prevalence of Gas6 polymorphisms (Gas6 c. 834 þ 7G > A) in patients with SPS and healthy controls in Slovak population. Our results are discordant to those of Muñoz who found allele A to be more prevalent in healthy individuals and very rare in patients with thrombosis. According to our findings, allele G (homozygous or heterozygous) is present in the majority of SPS patients and healthy controls, and there are no significant differences between these 2 groups in the prevalence of Gas6 genotypes. It is possible that there is no relation between Gas6 polymorphism and SPS indeed. Thus, there is a question whether we may consider Gas6 polymorphism as a causative factor of SPS at all. However, if allele G is supposed to be more associated with thrombosis and it is equally common in both the patients with SPS and healthy controls, can we say that Slovak population is predisposed to thrombophilia in general? Certainly we have no evidence for this hypothesis. Probably other genetic mechanisms than Gas6 polymorphism can be involved in the etiology of SPS. However, further studies including more patients and healthy controls are needed to verify the relation of Gas6 polymorphisms to SPS in our population.
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